A First-in-Human Phase 1 Safety and Biodistribution of [177Lu]Lu-ABY-271 in Subjects With HER2-positive Metastatic Breast Cancer

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 6, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

June 1, 2028

Conditions

Metastatic Breast CancerHER2 + Breast Cancer

Interventions

DRUG

[177Lu]Lu-ABY-271

A single infusion of \[177Lu\]Lu-ABY-271

Trial Locations (3)

RECRUITING

Sahlgrenska University Hospital, Gothenburg

RECRUITING

Karolinska University Hospital, Stockholm

RECRUITING

Akademiska Sjukhuset, Uppsala